Languages English
Supported Assets
NVAXc logo

Novavax

24/7

Open Mo

-

-over selected period

Last close
$9.68
Premium / discount
-
Updated Reference Yahoo Finance ·

Price differences before fees and execution costs. Compare prices

Insights

Investors weigh if Novavax's partnership royalty model can beat policy headwinds and reach profit, or if execution gaps and cash strain will halt progress.

Partner‑driven royalty and milestone execution

Partners such as Sanofi and Takeda are set to commercialize the XFG‑variant Nuvaxovid for the 2026‑2027 season, enabling Novavax to earn royalties and milestones without its own sales force.

Royalty and milestone flows could prove too small or lumpy, leaving Novavax exposed if partner sales or regulatory timing fall short.

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach - Simply Wall St NewsDo Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach - Simply Wall St News

Impact of the Protecting Approved Care Act

The Protecting Approved Care Act focuses on Medicare Advantage mechanics and does not appear directly material to Novavax's current revenue drivers, limiting its policy impact.

Bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices.

Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?Novavax (NVAX) Draws Focus On Policy Reform, Is It 34% Overvalued? - Simply Wall St News

Path to non‑GAAP profitability by 2028

Management targets non‑GAAP profitability by 2028 through expense reductions and a revenue mix shift toward high‑margin royalties, supported by $724M cash.

Novavax posted a $53.4 million Q2 2026 net loss and negative 59.87% profit margins, and relies on milestone payments before its $723.9 million cash runway exhausts.

Novavax's Matrix-M Pivot: The Catalysts Are Real, the Money Is Milestone-ShapedMatrix-M Platform Pivot: Can Novavax's Partnership Model Deliver Profits by 2028? (NASDAQ:NVAX) - NVAX Analysis - EveryTickerNovavax's Matrix-M Pivot: The Catalysts Are Real, the Money Is Milestone-ShapedMatrix-M Platform Pivot: Can Novavax's Partnership Model Deliver Profits by 2028? (NASDAQ:NVAX) - NVAX Analysis - EveryTicker

News

Token

Token
NVAXc
Shares per token
1.00000000 NVAX
Contract
0xb200000000000000000000c597c476fcf9aed3a8

Get Mo

Hold it in Mo

Hold NVAXc in a Mo smart wallet on Base that you control.

Move it fast

Send NVAXc to another Mo user for free, or transfer to any compatible Base wallet near-instantly.

Your money. More possibilities.